Senores Pharmaceuticals, Inc launched Deferiprone Tablets USP, 500 mg and 1000 mg, which is bioequivalent and therapeutically equivalent to Ferriprox Tablets of Chiesi USA, Inc in the US market. The product will be marketed by Dr Reddy's Laboratories Inc.

“We are pleased to advance our growth with the launch of a limited-competition product. This aligns with our strategic focus on identifying and entering a niche, under-penetrated generic formulations with an opportunity to serve the unmet needs in healthcare” stated Swapnil Shah, Managing Director, Senores Pharmaceuticals.

Deferiprone Tablets, 500 mg and 1000 mg brand and generic products, had US sales of approximately USD 70 million MAT for the twelve months ending in October 2025, according to symphony.